BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37259100)

  • 1. Chemoradiation for oesophageal cancer: the choice of treatment modality.
    Kitti PM; Faltinova M; Kauppi J; Räsänen J; Saarto T; Seppälä T; Anttonen AM
    Radiat Oncol; 2023 May; 18(1):93. PubMed ID: 37259100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Feith M; Friess H; Weichert W; Jesinghaus M; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2019 Apr; 14(1):66. PubMed ID: 30992022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random.
    Qian D; Chen X; Shang X; Wang Y; Tang P; Han D; Jiang H; Chen C; Zhao G; Zhou D; Cao F; Er P; Zhang W; Li X; Zhang T; Zhang B; Guan Y; Wang J; Yuan Z; Yu Z; Wang P; Pang Q
    Radiother Oncol; 2022 Sep; 174():1-7. PubMed ID: 35764191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiotherapy followed by oesophagectomy may be the optimal treatment option for lower thoracic oesophageal cancer with supraclavicular lymph node metastasis: An inverse probability of treatment-weighted analysis of SEER database.
    Chang X; Liu J; Zhao Y; Shi A; Yu H; Yu R; Wang W
    J Med Imaging Radiat Oncol; 2023 Sep; 67(6):676-683. PubMed ID: 37452459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Care and Outcomes of Elderly Esophageal Cancer Patients Not Meeting Age-based Criteria of the CROSS Trial.
    Verma V; Haque W; Zheng D; Osayande F; Lin C
    Am J Clin Oncol; 2019 Jan; 42(1):67-74. PubMed ID: 30216194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Canadian single institution real-world experience using the CROSS trial regimen in the treatment of oesophageal and gastroesophageal junction carcinoma.
    Khalid S; Hopman WM; Virik K
    Intern Med J; 2022 Sep; 52(9):1587-1595. PubMed ID: 34139041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
    Haque W; Verma V; Butler EB; Teh BS; Rusthoven CG
    Lung Cancer; 2019 Jan; 127():76-83. PubMed ID: 30642556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoradiation versus oesophagectomy for locally advanced oesophageal cancer in Chinese patients: study protocol for a randomised controlled trial.
    Jia R; Yin W; Li S; Li R; Yang J; Shan T; Zhou D; Wang W; Wan L; Zhou F; Gao S
    Trials; 2019 Apr; 20(1):206. PubMed ID: 30971301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
    Chen CJ; Yang CK; Jian JL; Guan S; Xie MM
    Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience.
    Laughlin BS; Petersen MM; Yu NY; Anderson JD; Rule WG; Borad MJ; Aqel BA; Sonbol MB; Mathur AK; Moss AA; Bekaii-Saab TS; Ahn DH; DeWees TA; Sio TT; Ashman JB
    J Gastrointest Oncol; 2022 Feb; 13(1):288-297. PubMed ID: 35284111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
    Wang BY; Wu SC; Chen HC; Hung WH; Lin CH; Huang CL; Chen HS
    Br J Surg; 2019 Feb; 106(3):255-262. PubMed ID: 30395362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.